APO-MONTELUKAST TABLET (CHEWABLE)
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
02-11-2021
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
MONTELUKAST (MONTELUKAST SODIUM)
から入手可能:
APOTEX INC
ATCコード:
R03DC03
INN（国際名）:
MONTELUKAST
投薬量:
5MG
医薬品形態:
TABLET (CHEWABLE)
構図:
MONTELUKAST (MONTELUKAST SODIUM) 5MG
投与経路:
ORAL
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription
治療領域:
LEUKOTRIENE MODIFIERS
製品概要:
Active ingredient group (AIG) number: 0133823001; AHFS:
認証ステータス:
APPROVED
承認日:
2019-04-26
製品の特徴
Page 1 of 31
PRODUCT MONOGRAPH
PR
APO-MONTELUKAST
montelukast (as montelukast sodium)
4 mg and 5 mg chewable tablets
Leukotriene Receptor Antagonist
APOTEX INC.
DATE OF REVISION:
150 Signet Drive
November 2, 2021
Toronto, Ontario
M9L 1T9
SUBMISSION CONTROL NO.: 256160
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE
REACTIONS........................................................................................................
7
DRUG INTERACTIONS
.......................................................................................................10
DOSAGE AND
ADMINISTRATION......................................................................................12
OVERDOSAGE
...................................................................................................................13
ACTION AND CLINICAL
PHARMACOLOGY.......................................................................13
STORAGE AND STABILITY
................................................................................................17
DOSAGE FORMS, COMPOSITION AND
PACKAGING..........................................................17
PART II: SCIENTIFIC
INFORMATION.................................................................................18
PHARMACEUTICAL INFORMATION
..................................................................................18
CLINICAL
TRIALS..............................................................................................................19
TOX
完全なドキュメントを読む
